Title : A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).

Pub. Date : 2019 Sep 2

PMID : 31477168

1 Functional Relationships(s)
Compound Name
Protein Name
1 Dual HER2 blockade with ado-trastuzumab emtansine (T-DM1) and lapatinib plus nab-paclitaxel has shown efficacy in patients with metastatic HER2-positive breast cancer. nab erb-b2 receptor tyrosine kinase 2 Homo sapiens